These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Lyvers M; Meester M J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892 [TBL] [Abstract][Full Text] [Related]
9. Replication and extension of a model predicting response to psilocybin. Russ SL; Carhart-Harris RL; Maruyama G; Elliott MS Psychopharmacology (Berl); 2019 Nov; 236(11):3221-3230. PubMed ID: 31203401 [TBL] [Abstract][Full Text] [Related]
10. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Griffiths R; Richards W; Johnson M; McCann U; Jesse R J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735 [TBL] [Abstract][Full Text] [Related]
11. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach]. Jastrzebski M; Bala A Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546 [TBL] [Abstract][Full Text] [Related]
12. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683 [TBL] [Abstract][Full Text] [Related]
13. Long-lasting subjective effects of LSD in normal subjects. Schmid Y; Liechti ME Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441 [TBL] [Abstract][Full Text] [Related]
17. Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI). Dworatzyk K; Jansen T; Schmidt TT PLoS One; 2022; 17(3):e0264927. PubMed ID: 35294453 [TBL] [Abstract][Full Text] [Related]
18. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use. Roberts CA; Osborne-Miller I; Cole J; Gage SH; Christiansen P J Psychopharmacol; 2020 Sep; 34(9):999-1007. PubMed ID: 32674668 [TBL] [Abstract][Full Text] [Related]
19. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Carbonaro TM; Johnson MW; Griffiths RR Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212 [TBL] [Abstract][Full Text] [Related]
20. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]